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Abstract
Background: Host genetic factors may be important determinants of HIV-1 sexual acquisition. We performed a genome-
wide association study (GWAS) for host genetic variants modifying HIV-1 acquisition and viral control in the context of a
cohort of African HIV-1 serodiscordant heterosexual couples. To minimize misclassification of HIV-1 risk, we quantified HIV-1
exposure, using data including plasma HIV-1 concentrations, gender, and condom use.
Methods: We matched couples without HIV-1 seroconversion to those with seroconversion by quantified HIV-1 exposure
risk. Logistic regression of single nucleotide polymorphisms (SNPs) for 798 samples from 496 HIV-1 infected and 302 HIV-1
exposed, uninfected individuals was performed to identify factors associated with HIV-1 acquisition. In addition, a linear
regression analysis was performed using SNP data from a subset (n=403) of HIV-1 infected individuals to identify factors
predicting plasma HIV-1 concentrations.
Results: After correcting for multiple comparisons, no SNPs were significantly associated with HIV-1 infection status or
plasma HIV-1 concentrations.
Conclusion: This GWAS controlling for HIV-1 exposure did not identify common host genotypes influencing HIV-1
acquisition. Alternative strategies, such as large-scale sequencing to identify low frequency variation, should be considered
for identifying novel host genetic predictors of HIV-1 acquisition.
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Introduction
HIV-1 interacts with many host factors during the process of
infection and replication. However, there is only one confirmed
example of a host factor variant that modifies HIV-1 infection
outcomes: CCR5- D32, a variant in the co-receptor for HIV-1
cellular entry has been shown to increase host resistance to HIV-
1 infection and HIV-1 disease progression [1–3]. While, CCR5-
D32 is relatively infrequent or absent in many populations, its
existence supports the need to broadly evaluate the human
genome for other host genetic variants that influence HIV-1
acquisition.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28632To date, broad evaluations for host genetic factors have been
most successful with identifying predictors of HIV-1 control in
infected individuals with recent genome-wide association studies
(GWAS) [4–6] identifying single nucleotide polymorphisms (SNPs)
in the Human Leukocyte Antigen (HLA) complex associated with
plasma HIV-1 set point, and disease non-progression [7], as well
as genes outside HLA associated with disease progression [8].
Studies looking for host genetic variation associated with HIV-1
acquisition have been more challenging. Candidate variation has
been evaluated in HLA, chemokines/chemokine receptors,
mediators of the innate, and adaptive immune responses, and
factors thought to underlie intracellular viral restriction in diverse
epidemiologic contexts (reviewed in reference [9]). To date, no
specific gene or variant has been found to consistently influence
HIV-1 acquisition/resistance across these diverse studies. Recent-
ly, a GWAS evaluated common SNPs across the human genome
comparing HIV-1 seropositive to seronegative Malawians and
found no common SNPs associated with HIV-1 infection [10].
However, interpretation of studies of HIV-1 acquisition is
complicated by the fact that levels of HIV-1 exposure are difficult
to quantify, and yet modify risk of HIV-1 sexual transmission by
up to 300-fold [11]. Lack of HIV-1 exposure quantification could
therefore result in reduced power to detect relevant common
variants due to misclassification in assigning HIV-1 acquisition
phenotypes (e.g., HIV-1 susceptible individuals with low HIV-1
exposure and therefore at low risk of HIV-1 acquisition who,
without quantitative assessment of exposure, are misclassified as
HIV-1 resistant).
The principal determinant of HIV-1 sexual transmission risk,
and therefore primary HIV-1 exposure factor, is the plasma HIV-
1 RNA level in the transmitting partner [12,13]. Other
epidemiologic, biologic and behavioral factors (e.g., circumcision
status of male uninfected partners, and frequency of unprotected
sex between partners) also contribute to this risk [11,14–16]. Thus,
accurate quantification of the level of HIV-1 exposure and
associated HIV-1 sexual transmission risk requires data from both
sexual partners.
Studies of HIV-1 serodiscordant couples (one partner HIV-1
infected and the other HIV-1 uninfected) offer unique advantages
for identifying factors associated with HIV-1 acquisition. In
particular, prospective collection of specimens and data from both
sexual partners facilitates quantification of HIV-1 exposure risk,
and confirmation of HIV-1 transmission linkage between partners.
Therefore, this study design allows HIV-1 uninfected individuals
with little to no HIV-1 exposure to be excluded from the analysis.
To date, no GWAS for host genetic factors underlying HIV-1
acquisition has been performed in a cohort of HIV-1 serodiscor-
dant couples. Here we report use of specimens and data from
African heterosexual HIV-1 serodiscordant couples in a GWAS
for host genetic predictors of HIV-1 acquisition and set point
plasma RNA levels.
Methods
Study Cohort
Study participants were selected from two cohorts of African
HIV-1 serodiscordant heterosexual couples:
1) The Partners in Prevention HSV/HIV Transmission Study
enrolled 3408 African HIV-1 serodiscordant couples at 14
sites in East and Southern Africa, and followed them
quarterly for up to 24 months to evaluate the efficacy of
herpes simplex virus type-2 (HSV-2) suppression to reduce
HIV-1 transmission to their heterosexual HIV-1 uninfected
partners [17,18]. HIV-1 infected partners in this trial were
required to be dually-infected with HSV-2 with a CD4 count
$250 cells/mm
3; there was no eligibility criterion related to
HSV-2 serostatus of the HIV-1 uninfected partner. The
primary analysis for this trial found acyclovir suppression
reduced plasma HIV-1 level of the HIV-1 infected partners
by a mean of 0.25 log10 copies/ml, but did not reduce the risk
of HIV-1 transmission [18].
2) The Couples Observational Study (COS) used a similar
recruitment process to enroll 485 HIV-1 serodiscordant
couples from Soweto, South Africa and Kampala, Uganda
without restriction on CD4 count or HSV-2 serostatus of the
HIV-1 infected partner; these couples were followed
quarterly for up to 12 months.
In both cohorts, HIV-1 serostatus in the initially HIV-1
uninfected partner was assessed by dual HIV-1 rapid assays and
HIV-1 seroconversions confirmed by ELISA, and Western blot or
RT-PCR [18]. Plasma HIV-1 env and gag sequencing of both
partners were compared with those consistent with transmission
linkage within the partnership classified as ‘‘linked’’ [18,19].
Seroconverting partners were also followed after seroconversion to
document plasma HIV-1 RNA set point and CD4 counts.
Among all participants recruited at both COS study sites and at
the 10 Partners in Prevention HSV/HIV Transmission Study sites
at which consent for host genetic studies had been obtained, a total
of 863 individuals were selected for genotyping. Procedures used
to identify these individuals are described below.
Sample selection
In order to identify HIV-1 non-seroconverting and serocon-
verting partners with similar ranges of HIV-1 exposure we
identified epidemiologic factors predicting HIV-1 transmission.
Baseline data from linked transmitting and non-transmitting
couples identified in the Partners in Prevention HSV/HIV
Transmission Study was used to develop a Cox proportional
hazards model identifying HIV-1 exposure factors associated with
HIV-1 transmission: gender, age, male circumcision, HIV-1
infected partner plasma RNA level, and unprotected sex.
Seroconverting couples in either cohort were matched to two
non-seroconverting couples based on baseline status for each HIV-
1 exposure factor. To augment power to detect genotypes
associated with host resistance to HIV-1 we also included
additional HIV-1 uninfected individuals with all HIV-1 exposure
factors in high-risk strata.
To facilitate comparisons of HIV-1 exposure levels we used the
regression coefficients of the Cox prediction model to develop an
exposure score that ranged from 0 (lowest exposure) to 7 (highest
exposure) (Table 1). The cumulative risk of HIV-1 infection for
individuals with an exposure risk score $2 was 31-fold greater
than for those with an exposure risk ,2 (4.99% vs 0.16%).
Among the 863 individuals identified for genotyping through
this process, 512 (59%) were HIV-1 infected (384 [75%] prevalent
and 127 [25%] incident HIV-1 infections) and 352 (41%)
remained HIV-1 uninfected despite documented HIV-1 exposure.
Table 2 provides a breakdown of the sample selection by HIV-1
infected and uninfected status.
Genotyping
Genomic DNA was extracted from 1 ml archived whole blood.
All samples were genotyped using Illumina HumanHap 1M-Duo
(np135) Bead Chips [20], which feature more than 1 million SNPs
including 21 directly genotyped variants that have been identified
in previous studies as associated with HIV-1 susceptibility [4].
GWAS for HIV-1 Acquisition
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,1% or with .5% missing results were excluded leaving 990,115
SNPs for association analysis. Bonferroni correction for multiple
testing used a P value cutoff of 5.1610
28 for genome-wide
significance.
Candidate SNP subset
As a subanalysis, we evaluated 21 candidate SNPs previously
implicated in HIV-1 infection that were present on the 1M-Duo
chip platform. We report uncorrected p-values for these 21 SNPs.
Statistical analysis
Sample exclusions. A total of 25 samples were excluded
based on genotyping quality control steps (twelve samples failed
genotyping,elevenhad genotype inconsistent with epidemiologically
assigned gender, and two failed cryptic relatedness require-
ments). Population structure was evaluated using a modified
EIGENSTRAT method [21], the first principal component
(eigenvector) discriminated individuals based on whether they
were from Southern African (South Africa and Botswana) or
Eastern African (Kenya, Uganda and Tanzania) study sites
(Figure S1); at this step, eight samples were removed as
population outliers.
Finally, in order to capture all HIV-1 infected individuals for
genotyping, the initial matching for HIV-1 exposure included all
seroconverting couples. Thus, some HIV-1 uninfected partners
were selected for genotyping by matching to HIV-1 exposure
scores of unlinked seroconverting couples; many of these HIV-1
uninfected partners had HIV-1 exposure risk scores,2. However,
since all couples with linked transmission had HIV-1 exposure
scores $2, we took this as an HIV-1 exposure cutoff and excluded
from analysis 32 HIV-1 uninfected individuals with exposure
score ,2.
Analysis of specific HIV-1 phenotypes. 1) HIV-1
susceptibility analysis: We evaluated genotypes for all HIV-1
seropositive individuals, including prevalent HIV-1 infections
Table 1. Identification of HIV-1 exposure factors through a predictive model of HIV-1 transmission.
Parameter
P-value
(linked infections) Parameter estimate Hazard Ratio Exposure Score
Any unprotected sex ,0.001 0.60 1.82 1
Male uninfected partner uncircumcised 0.028 0.59 1.81 1
Uninfected partner age,25 yrs 0.022 0.56 1.74 1
Infected partner plasma viral RNA (,10,000 copies/ml – baseline)
10–50,000 copies/ml ,0.001 1.32 3.75 2
50–100,000 copies/ml ,0.001 2.25 9.46 4
.100,000 copies/ml ,0.001 2.00 7.38 4
Baseline data from non-transmitting and linked transmitting couples from the Partners in Prevention HSV/HIV Transmission Study (N=3360) was used to develop a
predictive Cox regression model of HIV-1 transmission. An exposure risk score based on model regression coefficients was developed to quantify exposure risk and
confirm that participants selected for GWAS testing who had not seroconverted did have HIV-1 exposure.
doi:10.1371/journal.pone.0028632.t001
Table 2. Summary of Sample Selection for Genotyping.
Total couples genotyped
(% Exposure with score
$5)
Total
individuals
(% East Africa)
Prevalent
HIV-1+
(% East Africa)
Seroconverters
(% East Africa)
HIV-1
Uninfected
(% East Africa)
Participants from couples associated with seroconversion 127 (50) 254 (74.8%) 127 (74.8%) 127 (74.8%) –
Participants from
non-seroconverting couples
257 (43) 514 (75.9%) 257 (75.9%) – 257 (75.9%)
Unmatched
HIV-1 uninfected individuals
– 95 (82%) 0 0 95 (82%)
Total individuals for genotyping 863 (76.2%) 384 (75.5%) 127 (74.8%) 352 (77.6%)
Excluded Individuals
Failed genotyping 12 3 1 8
Gender mismatch 11 5 1 5
Cryptic relatedness 2 0 1 1
Exposure score,23 2 – – 3 2
Population outlier 8 2 2 4
Total participants included in
HIV-1 acquisition analysis
798 (76.1%) 374 (75.7%) 122 (75.4%) 302 (76.8%)
Total participants included in
HIV-1 set point analysis
403 (74.7%) 293 (74.4%) 110 (75.5%) –
doi:10.1371/journal.pone.0028632.t002
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infections (partners HIV-1 seronegative at enrollment who became
infected during follow-up). These were compared to genotypes for
all HIV-1 exposed, seronegative individuals (HIV-1 exposures
scores $2). We also compared genotypes of HIV-1 seropositive
individuals to the subset of all HIV-1 uninfected individuals with
all baseline HIV-1 exposure characteristics in the highest risk
strata. For both of these analyses, we performed standard logistic
regression, additive genetic model, in PLINK (version 1.07)
[22,23], using gender, age and the individual coordinates of six
EIGENSTRAT eigenvectors as covariates.
2) Plasma RNA set point analysis: Similar to previous analyses
[24] we defined the plasma HIV-1 RNA set point among
individuals with prevalent infection (partner who was HIV-1
infected at enrollment) as the average log10 plasma RNA level after
excluding RNA measurements taken at or after the initiation of
antiretroviral therapy (ART) or when CD4 count was ,200 cells/
mm
3. We required RNA measurements to be stable, with
measurements for each individual visually inspected for notable
discrepancies (e.g., no plasma HIV-1 RNA measurements from
each individual differing by .1 log copies/ml); we required a
minimum of 2 reliable and consistent measurements per
individual. For individuals with incident infection (e.g., HIV-1
seroconversion during follow-up) an estimated date of HIV-1
infection was established based on a combination of HIV-1
serology and plasma HIV-1 RNA PCR results, with HIV-1 set
point calculated as the average of all log10 plasma HIV-1 RNA
measurements taken 4 months or more after the estimated date of
infection [25]. For all analyses, plasma HIV-1 RNA levels below
the limit of detection (240 copies/mL) were set to 120 copies/mL.
For this analysis, we performed linear regression for set point using
age, gender, acyclovir randomization, seroprevalent vs. serocon-
verter status and five EIGENSTRAT eigenvectors as covariates.
Ethical Review
All individuals whose samples were evaluated through this
genotyping provided informed consent for storage of samples for
future research including genetic studies. Human subject review
and approval for this analysis was obtained at the University of
Washington and at local and affiliated institutional review boards
for study sites where participants were enrolled. The Partners in
Prevention HSV/HIV Transmission Study was registered with
ClinicalTrials.gov (#NCT00194519).
Results
Genome-wide common variation associated with HIV-1
acquisition
After quality control, 798 samples remained for analysis (496
from HIV-1 infected and 302 from HIV-1 uninfected individuals).
Table 3 shows epidemiological and clinical characteristics of these
individuals.
Table 3. Epidemiologic Characteristics of Individuals in HIV-1 Acquisition Analysis.
HIV-1 Infected Partners
Characteristic
Prevalent
HIV-1 infected Incident HIV-1 infected All
Number 374 122 496
% Female 205 (55%) 55 (45%) 260 (52%)
% recruited from East African sites 283 (76%) 92 (75%) 375 (76%)
Median age [range] (years) 32 [18–67] 30 [18–72] 31 [18–72]
Baseline plasma HIV-1 RNA level or plasma HIV-1 set point (median log10 copies/ml) 4.62 4.49 n/a
Baseline plasma HIV-1 RNA level of
HIV-1 infected partner (median log10 copies/ml)
n/a 4.26 n/a
Median CD4 count at enrollment (cells/ul) 413 n/a n/a
Transmission linkage confirmed* n/a 86 (70%) n/a
HIV-1 Uninfected Partners
Characteristic
Matched
HIV-1 uninfected
Additional unmatched
HIV-1 uninfected All
Number 223 79 302
% Female 110 (49%) 41 (52%) 151 (50%)
% recruited from East African sites 168 (75%) 64 (81%) 375 (77%)
Median age [range] (years) 31 [18–70] 28 [19–66] 30.5 [18–70]
Baseline HIV-1 exposure characteristics
Highly exposed (risk score $5) 13 (5.8%) 77 (97.5%) 90 (29.8%)
Baseline plasma HIV-1 RNA of
HIV-1 infected partner (median log10 copies/ml) 4.52 5.14 4.83
% male uncircumcised 62.8% 76.3% 66.2%
%a g e,25 years 65% 76% 67.9%
% reporting unprotected sex 24.7% 95% 43%
*Based on plasma virus sequencing HIV-1 env and gag of both transmitting and seroconverting partner-pairs.
doi:10.1371/journal.pone.0028632.t003
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genome-wide significance of p,5.1610
28 (Figure 1). Further-
more, a meta-analysis based on the two separate analyses for
Eastern and Southern African recruited individuals was consistent
with the results from the pooled analysis. An annotated list of all
SNPs with p,1610
25 based on the pooled analysis of Eastern and
Southern recruited Africans is provided (Table S1). Among the 21
SNPs available on the 1M-Duo chip platform that have previously
been implicated with HIV-1 acquisition, none were GWAS
significant; only two were significant at a p,0.05 threshold with
both of these having effects in the opposite direction from the
original findings: for rs2070729-IRF1 the G allele was linked to
increased susceptibility (p=0.01) in contrast to the original study,
[26], and for rs1800451-MBL2 the A allele was linked to reduced
susceptibility (p=0.02) in contrast to prior studies [27–32]
(Table S2).
Comparison of the 496 HIV-1 infected individuals to 90 HIV-1
uninfected individuals having the higher HIV-1 exposure risk
scores (.5 risk score) did not identify SNPs reaching genome-wide
significance.
Genome-wide common variation associated with HIV-1
set point
Among the 496 HIV-1 infected individuals in our cohort, 403
(81%) met the requirements for stable HIV-1 set point including
293 (73%) prevalent and 110 (27%) incident infections (Table 4).
Comparison of log10 plasma HIV-1 levels of prevalent and
incident infections showed no statistically significant difference
between them (p=0.14), so both groups were combined for
subsequent analyses. The overall median plasma HIV-1 level for
individuals included in this plasma HIV-1 set point analysis was
4.53 log10 copies/ml. The median plasma HIV-1 level of males
(n=180) was 4.57 log10 copies/ml compared to females (n=223)
4.51 log10 copies/ml (p=0.57). Linear regression performed on
these 403 HIV-1 infected individuals for the 990,115 SNPs that
passed quality control found no single SNP reaching genome-wide
significance (Figure 2). An annotated list of all markers obtaining a
P-value less than 1610
25 was generated using WGAviewer
software [16] (Table S3).
Discussion
We found no common SNPs associated with HIV-1 acquisition
at genome-wide significance. This result is consistent with a recent
GWAS of Africans recruited from a high-risk setting [10]. Our
study is the first to select participants based on HIV-1 exposure
levels ensuring that HIV-1 uninfected individuals had documented
risk for HIV-1 acquisition. Furthermore, we also found that,
among the subset of African HIV-1 infected participants with
stable plasma HIV-1 level (combining individuals with incident
and chronic HIV-1 infection), no SNPs on the 1M-Duo chip were
associated at genome-wide significance with plasma HIV-1 set
point. This is also similar to recent findings from a GWAS for
determinants of plasma HIV-1 set point in an African-American
cohort [6].
Three important limitations to this analysis must be considered
in interpreting our findings. First, our overall sample size (n=798
individuals passing quality control criteria) had sufficient power to
detect host genetic variants with large effect sizes: e.g., variants
with minor allele frequencies of 5% or 20% having a genotype
relative risk greater than 3.2 and 2.1, respectively. A larger cohort
would be needed to evaluate for host genetic factors associated
with smaller genotype relative risks. However, it is possible that
lower levels of linkage disequilibrium, particularly within the
MHC region in African populations, reduced our ability to
identify MHC genetic variants potentially associated to plasma
HIV-1 set point in this cohort. This was apparent in a previous
analysis for host genetic determinants of set point viral load in an
African-American cohort [6]. Although two of the top four SNPs
(rs10484434 and rs11755492 –Table S3) in our analysis for
determinants of set point are located physically close to the MHC
region, there is no evidence that these SNPs tag causative variants
within the MHC for our cohort. Additional studies and meta-
analyses of these SNPs may provide further information on
whether these SNPs may have a weak association with set point
Figure 1. Manhattan plot for analysis of HIV-1 acquisition. -log10(p) is plotted for all SNPs against physical location of each SNP in the genome
(listed by chromosome number 1 through 22, and X and XY). The threshold for genome-wide significance (P=5.1610
28) is indicated.
doi:10.1371/journal.pone.0028632.g001
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reducing our power to detect host genetic association with set
point, the lower levels of linkage disequilibrium in African
populations might have reduced our power to detect weaker host
genetic associations with HIV-1 acquisition.
Second, the set of common variants evaluated for association
with HIV-1 outcomes is based on HapMap data derived from
common variation in West African (Yoruban) populations and
likely does not capture detailed host variation across diverse
subSaharan African populations [33–35]. Our analysis of
population structure did provide clear discrimination of persons
of Southern African and Eastern African origin (Figure S1a and
S1b), However, improved databases of common host genetic
variation in East and Southern African populations are becoming
available through the recently completed 1000 genomes project
[36]. Nevertheless, the capacity to indirectly capture overall host
variation through linkage disequilibrium will still be lower in
African populations due to lower levels of linkage disequilibrium
present in African populations [35,37].
Finally, recent studies suggest that low frequency or rare host
variation that cannot be readily captured through GWAS analysis
is an important source of factors contributing to human disease
causation [38,39]. Such causal rare variation can only be captured
through large-scale genome sequencing efforts.
A unique component to our analysis was our use of clinical and
behavioral factors from HIV-1 serodiscordant couples to quantify
overall HIV-1 exposure risk. This study design provides unique
advantages for controlling for epidemiological modifiers of HIV-1
acquisition – both explicitly for factors that are known to influence
HIV-1 acquisition (which we have done through the exposure
matching), and implicitly for any unidentified exposure factors
shared within the partnership. While consanguinity of partners is a
potential source of bias in this approach, across all samples, our
analysis found only 2 pairs of samples with cryptic relatedness, and
one sample from each cryptically related pair was excluded from
the analysis. Consistent with previous epidemiologic analyses of
HIV-1 transmission risk performed in this and other cohorts
[12,13,15,40], plasma HIV-1 RNA in the HIV-1 infected partner
has the greatest impact on estimated HIV-1 exposure level.
Although we also included additional factors from the HIV-1
uninfected partner (e.g., history of any unprotected sex, circum-
cision status of male HIV-1 uninfected partners, and age,35 years
for HIV-1 uninfected female partners) in our exposure risk
quantification, these factors contribute to a much smaller degree to
Table 4. Epidemiologic Characteristics of HIV-1 Infected Partners in HIV-1 Set Point Analysis.
Characteristic of HIV-1 Infected Participants for HIV-1 Set Point Analysis Prevalent HIV-1 Infected Incident HIV-1 infected All
Number 293 110 403
% Female 176 (60%) 47 (42.7%) 223 (55.3%)
% recruited from East African sites 218 (74%) 83 (75%) 301 (75%)
Median age [range] (years) 31 [18–67] 30 [18–54] 31 [18–67]
Baseline plasma HIV-1 RNA or plasma HIV-1 set point (median log10 c/ml) 4.57 4.49 4.53
Baseline plasma HIV-1 RNA level of HIV-1 infected partner (median log10 c/ml) n/a 4.17 n/a
Median CD4 count at enrollment (cells/ul) 436 n/a n/a
doi:10.1371/journal.pone.0028632.t004
Figure 2. Manhattan plot for analysis of plasma HIV-1 set point. -log10(p) is plotted for all SNPs against physical location of each SNP in the
genome (listed by chromosome number 1 through 22, and X and XY). The threshold for genome-wide significance is indicated.
doi:10.1371/journal.pone.0028632.g002
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the direction of transmission (male-to-female versus female-to-
male) since a recent per contact analysis for HIV-1 transmission
risk in this cohort found that, after adjusting for plasma HIV-1
levels, the relative risk for male-to-female versus female-to-male
transmission was 1.03 (p=0.93) [41]. Our HIV-1 exposure risk
score correlated well with overall proportion acquiring HIV-1
infection, with those having exposure scores $2 having a 31-fold
increased risk of HIV-1 infection. However, our overall analysis
included individuals with a range of HIV-1 exposure levels with
limited power to evaluate only those HIV-1 uninfected individuals
at the highest HIV-1 exposure levels. Finally, we also did not
account for longitudinal changes in exposure risk (e.g., HIV-1
infected partners initiating antiretroviral therapy resulting in
reduced plasma HIV-1 levels, or behavioral changes related to
frequency of sex or use of condoms). Thus, it remains an open
question whether the search for genomic factors underlying HIV-1
acquisition might benefit from identifying individuals with extreme
transmission phenotypes, e.g., those who remain HIV-1 seroneg-
ative despite persistently high HIV-1 exposures.
In summary, our GWAS comparing HIV-1 infected individuals
to HIV-1 uninfected individuals with documented HIV-1 exposure
risk did not identify host genetic factors strongly modifying risk of
HIV-1acquisition.FuturestudiesofHIV-1acquisitionand setpoint
determination may benefit from use of larger sample sizes,
identification of extreme transmission phenotypes, and large-scale
sequencing technologies to capture rare and previously unchar-
acterized common variants in these African cohorts.
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Figure S1 Plot of PC1 versus PC2 population substruc-
ture after removal of outliers. After removing the eight
outlier samples, EIGENSTRAT was re-run to obtain the
eigenvectors for use as covariates in association analysis. Graphical
plots are by A) Region, with black indicating individuals recruited
from study sites in Southern African countries (South Africa and
Botswana), and red indicating individuals recruited from study
sites in East African countries (Kenya, Uganda and Tanzania), and
B) HIV-1 status, with black indicating individuals who remained
HIV-1 seronegative, and red indicating HIV-1 seropositive
partners and individuals who seroconverted.
(DOC)
Table S1 SNPs associated with p,10
25 for HIV-1
susceptibility/resistance. SNP rs identifier, uncorrected p-
value, Chromosome number and basepair position (build 36.3,
hg18), a description of the relative position of the SNP in the
closest gene, Minor Allele Frequency (MAF) in HIV-1-negative
and HIV-1-positive populations, and name and distance to closest
gene are as indicated.
(DOC)
Table S2 List of tested variants previously reported to
have an association with HIV-1 susceptibility/resis-
tance. SNPs listed are those present on the Illumina HumanHap
1M-Duo (np135) Bead Chips that have been previously implicated
in candidate gene studies as having impact on HIV-1 acquisition.
Characteristics of the studies that reported those previous
associations are described.
(DOC)
Table S3 Variants with p,10
25 in HIV-1 set point
analysis. SNP rs identifier, uncorrected p-value, chromosome
number and basepair position (build 36.3, hg18), and name and
distance to closest gene are as indicated.
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